Welcome to the captivating realm of Breast Cancer Discovery! This exciting journey has reshaped the way we understand and combat one of the most widespread challenges faced by women globally. Brace yourself for a fascinating exploration into the world of medical…
A ‘One-Two Punch’ to Wipe Out Cancerous Ovarian Cells
Researchers from the University of Montreal Hospital Research Centre (CRCHUM) have developed a two-step combination therapy to destroy cancer cells. In a study published in the journal Nature Communications, they show the superior therapeutic effectiveness of the “one-two punch” on cells…
A Cancer Drug May Help Treat Human Papillomavirus Infections
HPV infections caused an estimated 266,000 deaths from cervical cancer worldwide in 2012, according to the World Health Organization. Routine screening by Pap smears or Human Papilloma Virus DNA tests has reduced death rates in developed countries compared to less developed…
Potential Treatment for Common Soft-tissue Childhood Cancer
Scientists have developed a potential new therapeutic approach for synovial sarcoma, one of the most common soft-tissue cancers in teenagers and young adults. At present the long-term survival rates for synovial sarcoma patients is well below 50 percent; a fact that…
Study Links Widely-used Drug Azathioprine to Skin Cancers
A drug used to treat inflammatory bowel disease, arthritis, and vasculitis as well as to prevent organ rejection in transplant patients has been identified as an essential contributor to Skin Cancer development, in a research study carried out at the University…
New Method Reveals How Well Cancer Drugs Hit Their Targets
Scientists have developed a technique that allows them to measure how well cancer drugs reach their targets inside the body. It shows individual cancer cells in a tumor in real time, revealing which cells interact with the drug and which cells…
ASCO: AstraZeneca pioneer Lynparza scores with Zytiga combo in prostate cancer
CHICAGO—At last year’s American Society of Clinical Oncology annual meeting, AstraZeneca posted Lynparza data that would eventually make it the first in its class to break into breast cancer. This time around, it’s trying to grab the same crown in prostate cancer….
Nanoparticles Take on Brain Cancer
Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median life expectancy for patients diagnosed with the disease is less than 15 months. MIT…
CAR-T Immunotherapy Eliminates Metastatic Colorectal Cancer in Mice
Immunotherapy has given patients and oncologists new options, which for some patients, has meant cures for diseases that had been untreatable. Colorectal cancer has a high mortality rate in advanced stages of the disease with few effective therapies. Researchers at the…
Merck’s Keytruda shows up its rivals with NICE backing in bladder cancer
Merck just accomplished a feat its rivals haven’t so far. Friday, England’s National Institute for Health and Care Excellence, the company’s Keytruda to treat certain bladder cancer patients, making it the first immuno-oncology med to win the cost watchdog’s favor for that use….